CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project develops a novel vaccine candidate for Respiratory Syncytial Virus (RSV) aimed at protecting vulnerable populations like infants and the elderly. The vaccine, TriVax, focuses on enhancing immune responses to key viral epitopes.
The development of a Respiratory Syncytial Virus (RSV) vaccine is deemed a global health priority by the World Health Organization.
Globally, RSV causes 33 million episodes of infection and up to 120,000 deaths annually.
The most affected populations are pre-term infants, young children and the elderly.
Several decades of intensive research are yet to yield a clinically approved vaccine.
This failure is mostly attributed to sophisticated viral mechanisms that prevent the induction of protective…
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
